Barr must wait until patent expiry for US generic argatroban entry
This article was originally published in Scrip
Barr Laboratories (part of Teva Pharmaceutical Industries) cannot launch its generic version of the direct thrombin inhibitor argatroban in the US until the expiry of the original product's formulation patent in mid-2014, an appeals court has ruled.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.